Skip to main content
TipRanks
Go Ultimate75% OFF

Invion (IVX) Share Price & Analysis

4 Followers

IVX Stock Chart & Stats

A$0.04A$0.00(12.12%)
At close: 4:00 PM GMT+11
AU$0.035AU$0.04AU$0.045Aug 24Sep 7Sep 18Oct 5Oct 19Nov 2Nov 16
Day’s Range
AUD 0.04 - AUD 0.04
52-Week Range
AUD 0.03 - AUD 0.11
Previous Close
AUD 0.03
Volume
N/A
Average Volume (3M)
63.07K
Market Cap
AUD 3.65M
Enterprise Value
AUD 4.42M
Total Cash (Recent Filing)
AUD 592.31K
Total Debt (Recent Filing)
AUD 1.55M
Price to Earnings (P/E)
―
Beta
-0.42
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Therapy Platform

A proprietary Photosoft™ platform gives Invion a defined technological base for developing photodynamic cancer treatments. Its light-activated approach is intended to selectively destroy cancer cells and may also stimulate anti-tumour immune responses, creating potential differentiation if clinical development succeeds.

Focused Oncology Pipeline

The company is focused on a substantial oncology opportunity rather than pursuing an unfocused portfolio. Initial work in breast and ovarian cancer, combined with nanoparticle delivery formulations, provides identifiable development programs around which future clinical validation and partnerships could be built.

Moderate Reported Leverage

Reported debt is moderate relative to the latest equity balance, so leverage is not currently the central financial constraint. This gives Invion more balance-sheet flexibility than a heavily indebted development company, although its ability to use that flexibility remains limited by losses and cash consumption.

Bears Say

Persistent Unprofitability

Recurring operating and net losses show that Invion has not yet converted its research activities into a profitable operating model. Continued losses can consume capital, restrict investment in clinical development, and make future financial performance dependent on achieving successful commercialization or securing additional funding.

Unstable And Weak Revenue Base

The sharp collapse in revenue and only limited recovery indicate an unstable commercial base rather than a durable growth trajectory. Such a low and volatile revenue run-rate provides little evidence of recurring market demand, leaving the company exposed to prolonged development timelines before meaningful operating scale emerges.

Ongoing Cash Burn And Reduced Resilience

Negative operating cash flow and mostly negative free cash flow indicate that Invion remains reliant on external capital or balance-sheet resources to fund operations. The accompanying erosion of equity materially reduces financial resilience and may constrain the duration and scale of ongoing research and development.

Invion News

IVX FAQ

What was Invion’s price range in the past 12 months?
Invion lowest share price was AU$0.03 and its highest was AU$0.11 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is AU$3.65M.
When is Invion’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Invion’s earnings last quarter?
Invion released its earnings results on Aug 27, 2026. The company reported -AU$0.021 earnings per share for the quarter.
Is Invion overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 110,553,130 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -AU$0.021 in its last earnings report. Following the earnings report the stock price went down -5.263%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in AU:IVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology